The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning: A causal mediation analysis approach

Xue Zou, Yiwen Zhu, John Jackson, Andrea Bellavia, Garrett M. Fitzmaurice, Franca Centorrino, Linda Valeri

Research output: Contribution to journalArticle

Abstract

To date, no study has evaluated the joint role of symptoms and adverse events as mediators of the effect of second-generation antipsychotics on patients' social functioning. We used recently developed methods for mediation analysis with multiple mediators to clarify the interplay of adverse events and symptoms in explaining the effects of paliperidone (R code for implementing the mediation analysis for multiple mediators is provided). We used data from 490 participants in a 6-week randomized dose-response trial that assigned three fixed dosages of ER OROS paliperidone (3, 9, and 15 mg/day). The primary outcome was an individual's score on the social performance scale assessed after 6 weeks. The sum of Positive and Negative Syndrome Scale (PANSS), weight gain, and extrapyramidal symptoms measured via the Simpson-Angus Scale after 5 weeks were investigated as potential mediators and effect modifiers of treatment effects. Results from mediation analyses showed that the improvements in social functioning are partly explained by reduction in PANSS symptoms. Suggestive evidence that adverse events could play a role as mediators was found. In particular, weight gain displayed a non-linear relationship with social functioning, whereby beneficial effects observed at small levels of weight gain were reduced in the presence of excessive weight gain. In conclusion, we found that the short-term effects of paliperidone on social functioning were dependent on the successful reduction in PANSS symptoms and possibly the occurrence of excessive weight gain, thus suggesting future directions for treatment and interventions.

Original languageEnglish (US)
Article number13
Journalnpj Schizophrenia
Volume4
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Weight Gain
Cohort Effect
Antipsychotic Agents
Joints
Paliperidone Palmitate
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning : A causal mediation analysis approach. / Zou, Xue; Zhu, Yiwen; Jackson, John; Bellavia, Andrea; Fitzmaurice, Garrett M.; Centorrino, Franca; Valeri, Linda.

In: npj Schizophrenia, Vol. 4, No. 1, 13, 01.12.2018.

Research output: Contribution to journalArticle

Zou, Xue ; Zhu, Yiwen ; Jackson, John ; Bellavia, Andrea ; Fitzmaurice, Garrett M. ; Centorrino, Franca ; Valeri, Linda. / The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning : A causal mediation analysis approach. In: npj Schizophrenia. 2018 ; Vol. 4, No. 1.
@article{b09bfe1e111f4fe0bbfa478d01a89bc9,
title = "The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning: A causal mediation analysis approach",
abstract = "To date, no study has evaluated the joint role of symptoms and adverse events as mediators of the effect of second-generation antipsychotics on patients' social functioning. We used recently developed methods for mediation analysis with multiple mediators to clarify the interplay of adverse events and symptoms in explaining the effects of paliperidone (R code for implementing the mediation analysis for multiple mediators is provided). We used data from 490 participants in a 6-week randomized dose-response trial that assigned three fixed dosages of ER OROS paliperidone (3, 9, and 15 mg/day). The primary outcome was an individual's score on the social performance scale assessed after 6 weeks. The sum of Positive and Negative Syndrome Scale (PANSS), weight gain, and extrapyramidal symptoms measured via the Simpson-Angus Scale after 5 weeks were investigated as potential mediators and effect modifiers of treatment effects. Results from mediation analyses showed that the improvements in social functioning are partly explained by reduction in PANSS symptoms. Suggestive evidence that adverse events could play a role as mediators was found. In particular, weight gain displayed a non-linear relationship with social functioning, whereby beneficial effects observed at small levels of weight gain were reduced in the presence of excessive weight gain. In conclusion, we found that the short-term effects of paliperidone on social functioning were dependent on the successful reduction in PANSS symptoms and possibly the occurrence of excessive weight gain, thus suggesting future directions for treatment and interventions.",
author = "Xue Zou and Yiwen Zhu and John Jackson and Andrea Bellavia and Fitzmaurice, {Garrett M.} and Franca Centorrino and Linda Valeri",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41537-018-0054-8",
language = "English (US)",
volume = "4",
journal = "npj Schizophrenia",
issn = "2334-265X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning

T2 - A causal mediation analysis approach

AU - Zou, Xue

AU - Zhu, Yiwen

AU - Jackson, John

AU - Bellavia, Andrea

AU - Fitzmaurice, Garrett M.

AU - Centorrino, Franca

AU - Valeri, Linda

PY - 2018/12/1

Y1 - 2018/12/1

N2 - To date, no study has evaluated the joint role of symptoms and adverse events as mediators of the effect of second-generation antipsychotics on patients' social functioning. We used recently developed methods for mediation analysis with multiple mediators to clarify the interplay of adverse events and symptoms in explaining the effects of paliperidone (R code for implementing the mediation analysis for multiple mediators is provided). We used data from 490 participants in a 6-week randomized dose-response trial that assigned three fixed dosages of ER OROS paliperidone (3, 9, and 15 mg/day). The primary outcome was an individual's score on the social performance scale assessed after 6 weeks. The sum of Positive and Negative Syndrome Scale (PANSS), weight gain, and extrapyramidal symptoms measured via the Simpson-Angus Scale after 5 weeks were investigated as potential mediators and effect modifiers of treatment effects. Results from mediation analyses showed that the improvements in social functioning are partly explained by reduction in PANSS symptoms. Suggestive evidence that adverse events could play a role as mediators was found. In particular, weight gain displayed a non-linear relationship with social functioning, whereby beneficial effects observed at small levels of weight gain were reduced in the presence of excessive weight gain. In conclusion, we found that the short-term effects of paliperidone on social functioning were dependent on the successful reduction in PANSS symptoms and possibly the occurrence of excessive weight gain, thus suggesting future directions for treatment and interventions.

AB - To date, no study has evaluated the joint role of symptoms and adverse events as mediators of the effect of second-generation antipsychotics on patients' social functioning. We used recently developed methods for mediation analysis with multiple mediators to clarify the interplay of adverse events and symptoms in explaining the effects of paliperidone (R code for implementing the mediation analysis for multiple mediators is provided). We used data from 490 participants in a 6-week randomized dose-response trial that assigned three fixed dosages of ER OROS paliperidone (3, 9, and 15 mg/day). The primary outcome was an individual's score on the social performance scale assessed after 6 weeks. The sum of Positive and Negative Syndrome Scale (PANSS), weight gain, and extrapyramidal symptoms measured via the Simpson-Angus Scale after 5 weeks were investigated as potential mediators and effect modifiers of treatment effects. Results from mediation analyses showed that the improvements in social functioning are partly explained by reduction in PANSS symptoms. Suggestive evidence that adverse events could play a role as mediators was found. In particular, weight gain displayed a non-linear relationship with social functioning, whereby beneficial effects observed at small levels of weight gain were reduced in the presence of excessive weight gain. In conclusion, we found that the short-term effects of paliperidone on social functioning were dependent on the successful reduction in PANSS symptoms and possibly the occurrence of excessive weight gain, thus suggesting future directions for treatment and interventions.

UR - http://www.scopus.com/inward/record.url?scp=85052671024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052671024&partnerID=8YFLogxK

U2 - 10.1038/s41537-018-0054-8

DO - 10.1038/s41537-018-0054-8

M3 - Article

C2 - 29950691

AN - SCOPUS:85052671024

VL - 4

JO - npj Schizophrenia

JF - npj Schizophrenia

SN - 2334-265X

IS - 1

M1 - 13

ER -